| Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912) |
|---|
| 08/04/2011 | WO2011093816A1 Dry powder formulation comprising a pharmaceutical combination of tiotropium bromide, formoterol fumarate and mometasone furoate |
| 08/04/2011 | WO2011093813A1 Dry powder pharmaceutical composition comprising tiotropium and fluticasone |
| 08/04/2011 | WO2011093812A2 Pharmaceutical formulation comprising tiotropium and budesonide in dry powder form |
| 08/04/2011 | WO2011093811A2 Pharmaceutical preparations comprising formoterol and fluticasone |
| 08/04/2011 | WO2011093809A2 Dry powder pharmaceutical composition comprising tiotropium and ciclesonide |
| 08/04/2011 | WO2011093742A2 Agent for treating parkinson's disease |
| 08/04/2011 | WO2011093672A2 Bicyclic heteroaryl derivatives having inhibitory activity for protein kinase |
| 08/04/2011 | WO2011093664A2 Anti-obesity composition containing (1s,2s,3s,4s)-5-aminocyclopentane-1,2,3,4-tetraol |
| 08/04/2011 | WO2011093647A2 Genes implicated in osteoarthritis and use thereof |
| 08/04/2011 | WO2011093612A2 Oral complex composition comprising pseudoephedrine and levocetirizine |
| 08/04/2011 | WO2011093600A2 Skin wound healing agent containing decursin and decursinol angelate |
| 08/04/2011 | WO2011093559A1 Composition for the prevention or treatment of gastric cancer containing ursodeoxycholic acid as an active ingredient |
| 08/04/2011 | WO2011093535A1 Matrix pharmaceutical composition containing galantamine |
| 08/04/2011 | WO2011093524A1 Di - substituted pyridine derivatives as anticancers |
| 08/04/2011 | WO2011093522A1 A cycloalkane derivative |
| 08/04/2011 | WO2011093512A1 Compounds for suppressing a peripheral nerve disorder induced by an anti - cancer agent |
| 08/04/2011 | WO2011093501A1 Gpr119 agonist |
| 08/04/2011 | WO2011093498A1 Loxoprofen-containing pharmaceutical composition |
| 08/04/2011 | WO2011093483A1 Therapeutic agent for hepatitis c |
| 08/04/2011 | WO2011093470A1 Pharmaceutical composition for treatment of bone diseases, which contains protein comprising bone morphogenetic protein receptor 1b (bmpr1b) extracellular domain or mutant thereof |
| 08/04/2011 | WO2011093469A1 Expression promoter for redox-related factor |
| 08/04/2011 | WO2011093441A1 Therapeutic or prophylactic agent for biliary diseases |
| 08/04/2011 | WO2011093415A1 Composition for control of animal parasites, and method for control of animal parasites |
| 08/04/2011 | WO2011093365A1 Nitrogenated heterocyclic compound |
| 08/04/2011 | WO2011093352A1 Thiazole derivative |
| 08/04/2011 | WO2011093308A1 Prophylactic or therapeutic agent for crohn's disease comprising organic acid polymer as active ingredient |
| 08/04/2011 | WO2011093294A1 Process for preparation of cephalosporin derivative |
| 08/04/2011 | WO2011092840A1 Method for manufacturing polymethoxyflavones that are highly stable over time and have reduced residual pesticide levels |
| 08/04/2011 | WO2011092835A1 Antiseptic solution for continuous oral disinfection |
| 08/04/2011 | WO2011092695A1 Quinazoline-based t cell proliferation inhibitors |
| 08/04/2011 | WO2011092690A1 Compositions and methods for prevention and treatment of pulmonary hypertension |
| 08/04/2011 | WO2011092671A1 Proline derivatives for use in the treatment of diabetes |
| 08/04/2011 | WO2011092556A1 Novel polymorph of the hydrochloride of the (4-hydroxycarbamoyl-phenyl)-carbamic acid (6-dimethylamino methyl-2-naphtalenyl) ester |
| 08/04/2011 | WO2011092551A1 Antimicrobial composition |
| 08/04/2011 | WO2011092547A1 Triazine-aryl-bis-indoles and process for preparation thereof |
| 08/04/2011 | WO2011092505A1 S100 protein binding interaction inhibitors |
| 08/04/2011 | WO2011092469A1 1-(5-tert-butyl-2-phenyl-2h-pyrazol-3-yl)-3-[2-fluoro-4-(1-methyl-2-oxo-2,3-dihydro-1h-imidazo[4,5-b]pyridin-7-yloxy)-phenyl]-urea and related compounds and their use in therapy |
| 08/04/2011 | WO2011092338A1 Combined treatment of pancreatic cancer with gemcitabine and masitinib |
| 08/04/2011 | WO2011092299A1 Oily composition rich in dha monoglycerides |
| 08/04/2011 | WO2011092290A1 Pyrazolo[5,1b]oxazole derivatives as crf-1 receptor antagonists |
| 08/04/2011 | WO2011092284A1 Novel amino acid derivatives and their use as gpr43 receptor modulators |
| 08/04/2011 | WO2011092273A1 Treatment of gist with masitinib |
| 08/04/2011 | WO2011092272A1 Gamma secretase modulaters |
| 08/04/2011 | WO2011092198A1 5-alkynyl-pyrimidines |
| 08/04/2011 | WO2011092197A1 5-alkynyl pyrimidines and their use as kinase inhibitors |
| 08/04/2011 | WO2011092187A1 Oxygen-substituted 3-heteroaroylamino-propionic acid derivatives and their use as pharmaceuticals |
| 08/04/2011 | WO2011092158A1 4 ' - azido - nucleosides as anti - hcv compunds |
| 08/04/2011 | WO2011092140A1 Pyrazole compounds as crth2 antagonists |
| 08/04/2011 | WO2011092128A1 Substituted naphthyridines and their use as syk kinase inhibitors |
| 08/04/2011 | WO2011092127A1 14,17-bridged estratriene derivatives comprising heterocyclic bioisosteres for the phenolic a-ring |
| 08/04/2011 | WO2011092120A1 6,7- dihydroimidazo [1,5-a] pyrazin-8 (5h) - one derivatives as protein kinase modulators |
| 08/04/2011 | WO2011092088A1 Sulfonamido derivatives of 3,4-diarylpyrazoles as protein kinase inhibitors |
| 08/04/2011 | WO2011092065A1 Nitric oxide releasing compounds for the treatment of neurophatic pain |
| 08/04/2011 | WO2011092061A1 Chromen-2-one derivatives and their use as monoamine neurotransmitter re-uptake inhibitors |
| 08/04/2011 | WO2011091973A1 5-nitro-8-hydroxyquinolines as inhibitors of cathepsin b |
| 08/04/2011 | WO2011091892A1 A method for late post coital contraception using ulipristal acetate |
| 08/04/2011 | WO2011091890A1 A method for post coital contraception in overweight for obese female subjects using ulipristal acetate |
| 08/04/2011 | WO2011091816A1 Pharmaceutical composition with anti-obesity activity comprising a premixture of pure orlistat and preparation process |
| 08/04/2011 | WO2011091807A1 Anticoagulant and glutathione for treatment of cancer |
| 08/04/2011 | WO2011091778A1 Production and use of antibacterial, antiproliferative, and antiphytopathogenic benzanthracenes |
| 08/04/2011 | WO2011091757A1 Polyheterocyclic compounds highly potent as hcv inhibitors |
| 08/04/2011 | WO2011091719A1 Crystalline hydrates of alkyl acyl acetaldehyde sulfite, preparation methods and uses thereof |
| 08/04/2011 | WO2011091710A1 Phenyl c-glucoside derivatives, preparation methods and uses thereof |
| 08/04/2011 | WO2011091692A1 Uses of benzoate and its derivatives |
| 08/04/2011 | WO2011091614A1 7-(2-substituted-3-amino-1-tetrahydropyrrolo[3,4-c]pyrazolyl)quinoline carboxylic acid derivatives, their preparation methods and uses against bacterium and tuberculosis |
| 08/04/2011 | WO2011091532A1 Hepatitis c inhibitor compounds |
| 08/04/2011 | WO2011091513A1 Polymorphic forms of lubiprostone |
| 08/04/2011 | WO2011091461A1 Compounds for use in the treatment of diseases |
| 08/04/2011 | WO2011069958A3 Low caloric fat replacers |
| 08/04/2011 | WO2011068897A9 Method for removing cytokines from blood with surface immobilized polysaccharides |
| 08/04/2011 | WO2011067356A3 Polymorphs of a mek inhibitor |
| 08/04/2011 | WO2011067348A3 Mek inhibitor salts and solvates thereof |
| 08/04/2011 | WO2011064395A3 Inhibitors and antagonists of calcium channels in the treatment of asthma |
| 08/04/2011 | WO2011049948A4 Neuroprotection and myelin repair using nestorone® |
| 08/04/2011 | WO2011041729A3 Compounds as lysophosphatidic acid receptor antagonists |
| 08/04/2011 | WO2011041304A3 Antimalarial agents that are inhibitors of dihydroorotate dehydrogenase |
| 08/04/2011 | WO2011038356A3 Novel liver-targeting agents and their synthesis |
| 08/04/2011 | WO2011038124A3 Systems and methods for treating depression, including the use of neurobehavioral tasks |
| 08/04/2011 | WO2011037913A3 Methods for preventing oxidative stress injury of a tissue by a folate-tempol conjugate |
| 08/04/2011 | WO2011035314A3 Vitamin d2 enriched mushrooms and fungi for treatment of oxidative stress, alzheimer's disease and associated disease states |
| 08/04/2011 | WO2011035143A3 Methods and compositions for inhibiting rho-mediated diseases and conditions |
| 08/04/2011 | WO2011032000A9 Method for protection of antimicrobial and anticancer drugs from inactivation by nitric oxide |
| 08/04/2011 | WO2011031621A3 High strength seamless alginate capsules |
| 08/04/2011 | WO2011031482A3 Treatment of 'iq motif containing gtpase activating protein' (iqgap) related diseases by inhibition of natural antisense transcript to iqgap |
| 08/04/2011 | WO2011031100A3 Aripiprazole-bentonite-aea hybrid, pharmaceutical composition containing the same and method for preparing the same |
| 08/04/2011 | WO2011028947A3 Heterocyclic compounds for the inhibition of pask |
| 08/04/2011 | WO2011019685A3 Second generation fatty acid compositions, formulations, and methods of use and synthesis thereof |
| 08/04/2011 | WO2011005681A8 Inhibiting inflammation with milk oligosaccharides |
| 08/04/2011 | WO2011005595A3 2-5a analogs and their methods of use |
| 08/04/2011 | WO2011001400A9 Processes for the preparation of form i and form ii of palonosetron hydrochloride |
| 08/04/2011 | WO2010151852A3 Protease inhibitors, compositions and methods of use |
| 08/04/2011 | WO2010129799A3 Treatment of lipid transport and metabolism gene related diseases by inhibition of natural antisense transcript to a lipid transport and metabolism gene |
| 08/04/2011 | WO2010127237A3 Cyclic inhibitors of 11beta-hydroxysteroid dehydrogenase 1 |
| 08/04/2011 | WO2010095768A8 4 -isopropylphenyl glucitol compounds as sglt1 inhibitors |
| 08/04/2011 | WO2008133534A3 Carbohydrate-lipid constructs and their use in preventing or treating viral infection |
| 08/04/2011 | WO2003057161A3 BENZOTHIENO [3,2-c]PYRAZOLYL AND BENZOFURANO [3,2-c] PYRAZOLYL COMPOUNDS, THEIR USE IN DISEASES ASSOCIATED WITH THE 5-HT2C RECEPTOR AND INTERMEDIATE COMPOUNDS THEREOF |
| 08/04/2011 | US20110191868 Methods for identification and use of agents targeting cancer stem cells |
| 08/04/2011 | US20110190876 Device for local and/or regional delivery employing liquid formulations of therapeutic agents |
| 08/04/2011 | US20110190688 Permeant Delivery System and Methods for Use Thereof |
| 08/04/2011 | US20110190515 Substituted 1,3-diphenylprop-2-en-1-one derivatives, preparation and uses thereof |